New developments in the treatment of osteoarthritis – focus on biologic agents

Jose Ignacio Torrero,1 Carlos Martínez2 1BioTrauma Centre, Escaldes, Principality of Andorra; 2University of Illinois Hospital and Health Sciences System, Chicago, IL, USA Abstract: Osteoarthritis (OA) is one of the most common diseases around the world. Medical, social, and financial co...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Torrero JI, Martínez C
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://doaj.org/article/42d743533a7d4b669d716675b5143794
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Jose Ignacio Torrero,1 Carlos Martínez2 1BioTrauma Centre, Escaldes, Principality of Andorra; 2University of Illinois Hospital and Health Sciences System, Chicago, IL, USA Abstract: Osteoarthritis (OA) is one of the most common diseases around the world. Medical, social, and financial consequences oblige clinicians, surgeons, and researchers to focus on finding the best treatment option, to eradicate and stop this degenerative joint disease, in order to avoid surgical options which in many instances are over-indicated. Noninvasive treatments, such as anti-inflammatory drugs, physiotherapy, orthotic devices, dietary supplements, have demonstrated lack of effectiveness. The possibility to perform intra-articular injections with hyaluronic acid, corticosteroids, or the newest but criticized treatment based on platelet-rich plasma (PRP) has changed the management of OA disease. The use of PRP has led to many differences in treatment since there is a lack of consensus about protocols, indications, number of doses, cost-effectiveness, and duration of the treatment. Many publications have suggested efficacy in tendon injuries, but when PRP has been indicated to treat cartilage injuries, things are more inconsistent. Some authors have reported their experience treating OA with PRP, and it seems that, if well indicated, it is an option as a supplementary therapy. Therefore, we need to understand that OA is a mechanical disease which not only produces changes in radiographs, but also affects the quality of life. Pathogenesis of OA has been well explained, providing us new knowledge and future possibilities to improve the clinical approach. From basic science to surgery, there is a great field we all need to contribute to, because the general population is aging and total joint replacements should not be the only solution for OA. So herein is an actual review of the developments for treating OA with biologics, intended to be useful for the population inside orthopedics who could be called bio-orthopedists, since OA is a molecular homeostasis disbalance between catabolism and anabolism triggered by mechanical stress. Keywords: plasma, platelets, interleukines, receptors, orthokine